Edgewise Therapeutics (EWTX) Share-based Compensation (2020 - 2026)

Edgewise Therapeutics has disclosed Share-based Compensation across 7 years of filings, most recently posting $8.7 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.7 million, down 3.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.4 million (up 19.06% YoY), and the FY2025 annual result was $34.8 million, up 40.63% from the prior year.
• Share-based Compensation came in at $8.7 million for Q1 2026 at Edgewise Therapeutics, down from $9.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $9.9 million in Q4 2025 to a low of $2.0 million in Q1 2022.
• The 5-year median for Share-based Compensation is $5.2 million (2023), against an average of $5.7 million.
• Across the five-year window, Share-based Compensation surged 568.24% in 2022 and decreased 3.8% in 2026, its largest moves.
• Edgewise Therapeutics' Share-based Compensation stood at $3.7 million in 2022, then surged by 37.93% to $5.2 million in 2023, then surged by 50.15% to $7.7 million in 2024, then rose by 27.63% to $9.9 million in 2025, then declined by 11.75% to $8.7 million in 2026.
• The last three Share-based Compensation figures came in at $8.7 million (Q1 2026), $9.9 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.